Premium
PROGESTOGEN THERAPY FOR ADVANCED CARCINOMA OF THE ENDOMETRIUM
Author(s) -
Kneale Barry,
Evans James
Publication year - 1969
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1969.tb107629.x
Subject(s) - progestogen , medicine , endometrium , radiation therapy , carcinoma , hormone , hormone therapy , oncology , biopsy , endometrial cancer , disease , cancer , urology , gynecology , breast cancer
Twenty‐seven patients with disseminated cancer of the endometrium were treated with progestogens. The diagnosis was confirmed by biopsy in 19 of these cases. A favourable response with tumour regression was noted in 13 patients (48%), the average duration of response being 27 months. The response was related to the site of metastatic disease, being greatest in patients with vaginal and incisional recurrences. Pelvic recurrences had the least favourable prognosis. Previous radiotherapy appeared to enhance the effect of the hormone, and poorly differentiated tumours were the least susceptible. There was no difference in response to different types of progestogen used, provided the dosage administered was of sufficient magnitude.